1. Bruce A. Chabner, Jeffery Barnes, Joel Neal, Erin Olson, Hamza Mujagic, Lecia Sequist, Wynham Wilson, Dan L. Longo, Constantine Mitsiades and Paul Richardson. Targeted Therapies: Tyrosine Kinase inhibitors, Monoclonal Antibodies and Cytokines. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1737-1738.
2. Gerald G. Briggs and Roger K. Freeman. L. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 2188-2190.
3. University of Kansas Medical Center. Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on February 2017] [Accessed 25th November 2020] https://clinicaltrials.gov/ct2/show/NCT01283789
4. Frans L. Opdam, Henk-Jan Guchelaar, Jos H. Beijnen, and Jan H.M. Schellens. Lapatinib for Advanced or Metastatic Breast Cancer. NCBI; PMC US National Library of Medicine, National Institute of Health. April 2012. [Accessed 25th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336826/
5. Catherine Oakman, Marta Pestrin, Elena Zafarana, Egidia Cantisani, and Angelo Di Leo. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. NCBI; PMC US National Library of Medicine, National Institute of Health. January 2010. [Accessed 25th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004582/
6. Novartis Pharma GmbH. Electronic Medicines Compendium (EMC); [Revised on October 2020] [Accessed 25th November 2020] https://www.medicines.org.uk/emc/files/pil.6292.pdf
7. GlaxoSmithKline. U.S. Food & Drug Administration. [Accessed 25th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf